Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date: July 11, 2025
Context: The filing discloses a regulatory update regarding the Company's lead cell therapy candidate, Deramiocel, intended for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
Key Financial Metrics
This Form 8-K is a regulatory disclosure and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Update
- FDA Complete Response Letter (CRL): The U.S. Food and Drug Administration (FDA) issued a CRL for the Biologics License Application (BLA) for Deramiocel.
- Reason for Non-Approval: The FDA stated the application does not meet the statutory requirement for substantial evidence of effectiveness and requires additional clinical data.
- CMC Issues: The CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls (CMC) section. The Company believes it had addressed most of these in prior communications, but they were not reviewed due to the timing of the CRL issuance.
- Review Status: The FDA confirmed the review clock will restart upon resubmission.
Guidance, Outlook, and Management Commentary
- Next Steps: Capricor plans to engage with the FDA to determine appropriate next steps and intends to request a Type A meeting to discuss the path forward.
- Resubmission Plan: The Company intends to resubmit its BLA in the third quarter of 2025.
- Supporting Data: The resubmission will include data from the ongoing Phase 3 HOPE-3 trial to support the indication for cardiomyopathy associated with DMD.
Investor Verification Checklist
- Verify the specific clinical data deficiencies cited in the FDA's CRL regarding "substantial evidence of effectiveness."
- Confirm the timeline and enrollment status of the Phase 3 HOPE-3 trial to ensure data availability for the Q3 2025 resubmission.
- Monitor the outcome of the requested Type A meeting with the FDA for clarity on the resubmission requirements.
- Review the status of the Chemistry, Manufacturing, and Controls (CMC) items to ensure they are fully resolved prior to resubmission.